Prognostic value of Glasgow Prognostic Score and its modified scores on 5-year outcome in patients with coronary heart disease undergoing percutaneous coronary intervention
Jiawen Li,
Kailun Yan,
Pei Zhu,
Xiaofang Tang,
Yuejin Yang,
Runlin Gao,
Jinqing Yuan,
Xueyan Zhao
Affiliations
Jiawen Li
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Kailun Yan
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Pei Zhu
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xiaofang Tang
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yuejin Yang
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Runlin Gao
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jinqing Yuan
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xueyan Zhao
National Clinical Research Center for Cardiovascular Diseases and State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background: Glasgow Prognostic Score (GPS) and its modified counterparts, including the modified GPS (mGPS) and hsCRP-modified GPS (hs-mGPS), are widely used inflammatory indices in clinical settings. Inflammation has gained increased attention in the context of coronary heart disease (CHD); however, its long-term predictive value in patients with CHD remains uncertain. Objective: This study aimed to assess the predictive values of GPS, mGPS, and hs-mGPS for long-term survival in patients following percutaneous coronary intervention (PCI). Methods: Consecutive 10,724 PCI patients were enrolled in 2013. The primary endpoint was 5-year all-cause death. Results: This study included 8,909 patients. Individuals with high GPS, mGPS, and hs-mGPS scores exhibited a significantly higher risk of all-cause death compared to those with low scores (all P < 0.05). All three indices (GPS, mGPS, and hs-mGPS) demonstrated predictive values for all-cause death, albeit with relatively low area under the curve values of 0.534, 0.522, and 0.545, respectively. Furthermore, we refined the hs-mGPS using cutoffs (hsCRP at 2 mg/L and albumin at 40 g/L) which are better suited for these patients, to establish the CHD-hs-mGPS. This modification significantly improved the prediction of all-cause death, outperformed the mGPS and demonstrated numerical superiority over both the GPS and hs-mGPS. Notably, only CHD-hs-mGPS exhibited a predictive value for both the ACS and non-ACS subgroups. Conclusion: In patients with CHD who underwent PCI, GPS, mGPS, and hs-mGPS demonstrated significant long-term predictive values for all-cause death. Our parameter-adjusted score, the CHD-hs-mGPS, is applicable to a broad population and moderately enhances the predictive accuracy, facilitating the early identification of patients at high risk of long-term death.
